Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients

Endocrine Regulations

Volumn 42, Issue 1, 2008, Pages 63-68

  Sibel, Bilgili ^a   Aydan C , Celebiler ^a   Aylin, Dogan ^a   Baysal, Karaca ^a  

^a MINISTRY OF HEALTH   (Turkey)

Author keywords

Adiponectin; Metabolic syndrome; Plasminogen activator inhibitor 1. obesity

Indexed keywords

ADIPONECTIN; C PEPTIDE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

EID: 77954406590     PISSN: 12100668     EISSN: 13360329     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. ALESSI MC, JUHAN-VAGUE: PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 26, 2200-2207, 2006
2. BAHIA L, AGUIAR LG, VILLELA N, BOTTINO D, GODOYMATOS AF, GELONEZE B, TAMBASCIA M, BOUSKELA E. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics 61, 433-440, 2006
3. BASTARD JP, PIERONI L, HAINQUE B: Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 16, 192-201, 2000
4. CRANDALL DL, BUSLER DE, MCHENDRY-RINDE B, GROELING TM, KRAL JG. Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1. J Clin Endocrinol Metab 85, 2609-2614, 2000
5. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18, 499-502, 1972
6. GUERRE-MILLA M: Adipose tissue and Adipokines: for beter or worse. Diabetes Metab 30, 13-19, 2004
7. HEINRICH J, BALLEISEN L, SCHULTE H, ASSMANN G, VAN DE LOO J: Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 14,:54-59, 1994
8. JUHAN-VAGUE I, ALESSI M, VAGUE P: Increased plasma PAI-1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34, 457-462, 1991
9. KIM SM, CHO KH, PARK HS: Relationship between plasma adiponectin levels and the metabolic syndrome among Korean people. Endocrine J 53, 247-254, 2006
10. MA LJ, MAO SL, TAYLOR KL, KANJANABUCH T, GUAN Y, ZHANG Y, BROWN NJ, SWIFT LL, MCGUINNESS OP, WASSERMAN DH, VAUGHAN DE, FOGO AB: Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53,:336-346, 2004
11. MARUYOSHI H, KOJIMA S, FUNAHASHI T, MIYAMOTO S, HOKAMAKI J, SOEJIMA H, SAKAMOTO T, KAWANO H, YOSHIMURA M, KITAGAWA A, MATSUZAWA Y, OGAVA H: Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 91, 1026-1030, 2004
12. MATTHEWS DR, HOSKER JP, RUDENSKI AS, NAYLOR BA, TREACHER DF, TURNER RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28, 412-419, 1985
13. MATSUZAWA Y: The metabolic syndrome and adipocytokines. FEBS Lett. 580, 2917-2921, 2006
14. MERTENS I, BELLAUX D, FUNAHASHI T, MATSUZAWA Y, VAN DER PLANKEN M, VERRIJKEN A, RUIGE JB, VAN GAAL LF: Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. Thromb Haemost 94, 1190-1195, 2005
15. MICZKE A, BRYL W, SZULINSKA M, PUPEK-MUSIALIK D: The role of adiponectin in pathogenesis of insulin resistance and metabolic syndrome. Pol Merkur Lekarski 19, 723-726, 2005
16. MOHAN V, DEEPA R, PRADEEPA R, VIMALESWARAN KS, MOHAN A, VELMURUGAN K, RADHA V Association of low adiponectin levels with the metabolic syndrome-the Chennai Urban Rural Epidemiology Study. Metabolism 54, 476-481, 2005
17. MOJIMINIYI OA, ABDELLA NA, AI AROUJ M, BEN NAKHI A. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int J Obes 31, 213-220, 2007
18. OKAMATO Y, KIHARA S, FUNAHASHI T, MATSUZAWA Y, LIBBY P: Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 110, 267-278, 2006
19. OUCHI N, SHIBATA R, WALSH K: Cardioprotection by adiponectin. Trends Cardiovasc Med 16,141-146, 2006
20. PANNACCIULLI N, MITRIO VD, MARINO R, GIORGINO R, PERGOLA GD: Effect of Glucose Tolerance Status on PAI-1 Plasma Levels in Overweight and Obese Subjects. Obesity Research. 10, 717-725, 2002
21. RYO M, NAKAMURA T, KIHARA S, KUMADA M, SHIBAZAKI S, TAKAHASHI M, NAGAI M, MATSUZAWA Y, FUNAHASHI T: Adiponectin as a biomarker of the metabolic syndrome. Circ J 68,:975-981, 2004
22. SANTANIEMI M, KESANIEMI YA, UKKOLA O: Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 155, 745-750, 2006
23. TAJTAKOVA M, PETRASOVA D, PETROVICOVA J, PYTLIAK M, SEMANOVA Z. Adiponectin as a biomarker of clinical manifestation of metabolic syndrome. Endocr Regul 40, 15-19, 2006
24. WHITEHEAD JP, RICHARDS AA, HICKMAN IJ, MACDONALD GA, PRINS JB: Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 8, 264-280, 2006
25. WORLD HEALTH ORGANIZATION. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. WHO/NCD/NCS 99.2. Geneva,1999.
26. WILSON PW, D'AGOSTINO RB, PARISE H, SULLIVAN L, MEIGS JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 15, 3066-3072, 2005